US OptionsDetailed Quotes
ROIV241115C14000
- 0.05
- 0.000.00%
15min DelayClose Nov 1 09:31 ET
0.00High0.00Low
0.05Open0.05Pre Close0 Volume351 Open Interest14.00Strike Price0.00Turnover62.84%IV20.29%PremiumNov 15, 2024Expiry Date0.00Intrinsic Value100Multiplier14DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type0.0806Delta0.1043Gamma233.60Leverage Ratio-0.0076Theta0.0003Rho18.83Eff Leverage0.0034Vega
Roivant Sciences Stock Discussion
» Holdings in Top 20: 86.71%
» Qtr over Qtr Change**: -9.29%
Top Holdings:
$Incyte (INCY.US)$
$BeiGene (BGNE.US)$
$ACADIA Pharmaceuticals (ACAD.US)$
$Madrigal Pharmaceuticals (MDGL.US)$
$Rhythm Pharmaceuticals (RYTM.US)$
$Revolution Medicines (RVMD.US)$
$Kymera Therapeutics (KYMR.US)$
$AbCellera Biologics (ABCL.US)$
$Bicycle Therapeutics (BCYC.US)$
$Edgewise Therapeutics (EWTX.US)$
$Immunocore (IMCR.US)$
$Kodiak Sciences (KOD.US)$
$Roivant Sciences (ROIV.US)$
...
Gapping up
$DoorDash (DASH.US)$ stock rose 0.4% after CFRA Research upgraded its investment stance on the food delivery platform to buy from hold, citing its high growth potential.
$Roivant Sciences (ROIV.US)$ stock rose 7.2% after the biotech said its experimental drug to treat non-infectious uveitis helped reduce symptoms of the inflammatory eye disease in a mid-stage study.
Gapping down
$NIO Inc (NIO.US)$ fell ...
$Leap Therapeutics (LPTX.US)$ Phase 2
$Vera Therapeutics (VERA.US)$ Phase 2b
$4D Molecular Therapeutics (FDMT.US)$ Phase 2
$Adverum Biotechnologies (ADVM.US)$ Phase 2
$Denali Therapeutics (DNLI.US)$ Phase 2
$Akero Therapeutics (AKRO.US)$ Phase 2b
$Spruce Biosciences (SPRB.US)$ Phase 2
$Xencor (XNCR.US)$ Phase 2
$Alnylam Pharmaceuticals (ALNY.US)$ Phase 2
$Harmony Biosciences (HRMY.US)$ Phase 2
$Annexon (ANNX.US)$ Phase 2a
$Roivant Sciences (ROIV.US)$...
$Regenxbio (RGNX.US)$ Phase 2
$Leap Therapeutics (LPTX.US)$ Phase 2
$4D Molecular Therapeutics (FDMT.US)$ Phase 2
$Adverum Biotechnologies (ADVM.US)$ Phase 2
$Denali Therapeutics (DNLI.US)$ Phase 2
$EyePoint Pharmaceuticals (EYPT.US)$ Phase 2
$Xencor (XNCR.US)$ Phase 2
$Harmony Biosciences (HRMY.US)$ Phase 2
$Alnylam Pharmaceuticals (ALNY.US)$ Phase 2
$Disc Medicine (IRON.US)$ Phase 2
$Atea Pharmaceuticals (AVIR.US)$ Phase 2
$Allakos (ALLK.US)$ Phase 2 ...
Bill Ackman Cashes Out Bet Against Treasury Bonds as Yields Hit 16-year Highs
One of Wall Street's most prominent bond bears has decided to walk away with his gains, declaring that Treasury yields are likely poised for a turnaround following an ascent that rattled global markets.
Pershing Square's Bill Ackman said Monday that he has closed his bet against 30-year Treasury bonds, saying in a ser...
No comment yet